Physician profile
David E Tanner
NPI 1609897578
$13,114.30
in general payments reported to CMS, 2019-2025
32 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Neuromusculoskeletal Medicine & Omm provider received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $568 · 2021: $9,371 · 2022: $897 · 2023: $770 · 2024: $495 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,336.40 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $899.09 | 2019-2021 | |
| Lundbeck LLC | $488.02 | 2024-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $324.93 | 2022 | |
| Upsher-Smith Laboratories LLC | $257.16 | 2020-2022 | |
| Merz Pharmaceuticals, LLC | $239.16 | 2021-2024 | Xeomin |
| Amgen INC. | $207.10 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $171.01 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $151.68 | 2022-2023 | Onzetra Xsail |
| Lilly USA, LLC | $126.62 | 2019-2023 | Emgality, Reyvow |
| Impel Pharmaceuticals INC. | $110.74 | 2023 | Trudhesa |
| Depuy Synthes Sales INC. | $105.11 | 2025 | Lcp |
| Promius Pharma LLC | $76.88 | 2019 | |
| Biodelivery Sciences International, INC. | $54.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.48 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $53.05 | 2019-2021 | |
| Pfizer INC. | $52.17 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $50.53 | 2021 | |
| Neurocrine Biosciences, INC. | $48.68 | 2022 | |
| Boston Scientific Corporation | $35.93 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $32.54 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $28.06 | 2021-2022 | |
| Axsome Therapeutics, INC. | $27.93 | 2023 | Auvelity |
| Zyla Life Sciences, INC. | $27.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.91 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $24.73 | 2020 | |
| Assertio Therapeutics, INC. | $24.60 | 2019 | |
| Merz North America, INC. | $24.02 | 2020 | |
| Si-Bone, INC. | $18.02 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.40 | 2020 | |
| Sentynl Therapeutics, INC. | $13.96 | 2019 | |
| Almatica Pharma LLC | $6.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.